Cartesian Therapeutics Inc (RNAC)
23.25
+0.04
(+0.19%)
USD |
NASDAQ |
May 08, 12:22
Cartesian Therapeutics Enterprise Value: 336.05M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 336.05M |
May 06, 2024 | 381.16M |
May 03, 2024 | 378.67M |
May 02, 2024 | 357.85M |
May 01, 2024 | 325.99M |
April 30, 2024 | 315.85M |
April 29, 2024 | 314.60M |
April 26, 2024 | 297.34M |
April 25, 2024 | 295.03M |
April 24, 2024 | 291.82M |
April 23, 2024 | 289.51M |
April 22, 2024 | 248.05M |
April 19, 2024 | 241.82M |
April 18, 2024 | 230.61M |
April 17, 2024 | 252.02M |
April 16, 2024 | 256.82M |
April 15, 2024 | 260.73M |
April 12, 2024 | 267.84M |
April 11, 2024 | 243.84M |
April 10, 2024 | 213.26M |
April 09, 2024 | 171.83M |
April 08, 2024 | 156.36M |
April 05, 2024 | -3.496M |
April 04, 2024 | 6.504M |
April 03, 2024 | 4.188M |
Date | Value |
---|---|
April 02, 2024 | 10.81M |
April 01, 2024 | 15.77M |
March 28, 2024 | 30.65M |
March 27, 2024 | 30.04M |
March 26, 2024 | 24.18M |
March 25, 2024 | 33.21M |
March 22, 2024 | 38.75M |
March 21, 2024 | 37.07M |
March 20, 2024 | 47.68M |
March 19, 2024 | 39.56M |
March 18, 2024 | 25.42M |
March 15, 2024 | 17.07M |
March 14, 2024 | 9.780M |
March 13, 2024 | 12.16M |
March 12, 2024 | 18.33M |
March 11, 2024 | 26.57M |
March 08, 2024 | 26.74M |
March 07, 2024 | 27.34M |
March 06, 2024 | 36.45M |
March 05, 2024 | 31.97M |
March 04, 2024 | 33.21M |
March 01, 2024 | 34.83M |
February 29, 2024 | 41.54M |
February 28, 2024 | 39.68M |
February 27, 2024 | 41.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.496M
Minimum
Apr 05 2024
444.30M
Maximum
Jun 14 2021
164.37M
Average
129.30M
Median
Feb 24 2023
Enterprise Value Benchmarks
Marinus Pharmaceuticals Inc | 8.378M |
Adial Pharmaceuticals Inc | 3.377M |
Poseida Therapeutics Inc | 129.10M |
Viracta Therapeutics Inc | 9.238M |
Biomea Fusion Inc | 286.42M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -177.66M |
Revenue (Quarterly) | 8.266M |
Total Expenses (Quarterly) | 44.60M |
EPS Diluted (Quarterly) | -41.70 |
Profit Margin (Quarterly) | -2.15K% |
Earnings Yield | -214.2% |
Normalized Earnings Yield | -105.04 |